

Highly Specialised Technologies Evaluation Committee Interests Register

Onasemnogene abeparvovec for treating pre-symptomatic spinal muscular atrophy (MAA partial review of HST 15)

Publication Date: 19/04/2023

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Emtiyaz Chowdhury	Committee Member	non-financial professional interest	he is an employee of Parexel who may have completed work for both manufacturers. He has not been directly involved with any work related to the technologies under consideration.		04/01/23		It was agreed that his declaration would not prevent Emtiyaz from participating in discussions on this evaluation.
Portia Thorman	Patient expert	Financial Interest	Her organisation, Spinal Muscular Atrophy UK, has received funding from the industry.		22/06/22		It was agreed that her declaration would not prevent Portia from providing expert advice to the committee.
Elizabeth Wraige	Clinical expert	Financial and non-financial interests	She has undertaken paid and unpaid consultancy work for Novartis and other manufacturers of spinal muscular atrophy modifying treatments. Prior to the meeting Elizabeth declared		29/06/22		It was agreed that her declarations would not prevent Elizabeth from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
			she is a member of the national SMA Reach clinical network (all paediatric neuromuscular consultants in England are members of this group) – this group meets regularly to review and discuss topics of importance with respect to standards of clinical care; She contributes data to the iSMAC registry (mandatory with respect to those patients receiving treatment through managed access agreement); She is co-chair of the national onasemnogene abeparvovec multidisciplinary team which oversees delivery of treatment through the 4 infusion centres.				
Laurent Servais	Clinical expert	Financial and non-financial interests	He has taken part in all trials for multiple sclerosis and he has conducted consultancy or been invited to lecture for		30/06/22		It was agreed that his declarations would not prevent Laurent from

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
			<p>Roche, Novartis and Biogen.</p> <p>He has conducted consultancy for Scholar Rock and Biohaven and he has had research funded by Novartis, Roche and Biogen. Prior to the meeting, Laurent declared he is Secretary of the world Muscle Society and vice-chair of the scientific advisory board of SMA Europe.</p>				providing expert advice to the committee.